Raffi Asadorian
2021 - AcelRx Pharmaceuticals
In 2021, Raffi Asadorian earned a total compensation of $1M as Chief Financial Officer at AcelRx Pharmaceuticals, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $151,082 |
|---|---|
| Option Awards | $272,262 |
| Salary | $460,616 |
| Stock Awards | $129,250 |
| Other | $11,400 |
| Total | $1,024,610 |
Asadorian received $460.6K in salary, accounting for 45% of the total pay in 2021.
Asadorian also received $151.1K in non-equity incentive plan, $272.3K in option awards, $129.3K in stock awards and $11.4K in other compensation.
Rankings
In 2021, Raffi Asadorian's compensation ranked 8,723rd out of 12,415 executives tracked by ExecPay. In other words, Asadorian earned more than 29.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,723 out of 12,415 | 30th |
Division Manufacturing | 3,867 out of 5,505 | 30th |
Major group Chemicals And Allied Products | 1,709 out of 2,375 | 28th |
Industry group Drugs | 1,520 out of 2,096 | 28th |
Industry Pharmaceutical Preparations | 1,132 out of 1,546 | 27th |
Source: SEC filing on June 3, 2022.
Asadorian's colleagues
We found two more compensation records of executives who worked with Raffi Asadorian at AcelRx Pharmaceuticals in 2021.
News
AcelRx Pharmaceuticals CEO Vincent Angotti's 2023 pay slips 7% to $1.2M
April 29, 2024
AcelRx Pharmaceuticals CEO Vincent Angotti's 2022 pay falls 47% to $1.3M
August 28, 2023
AcelRx Pharmaceuticals CEO Vincent Angotti's 2021 pay jumps 39% to $2.4M
June 3, 2022
AcelRx Pharmaceuticals CEO Vincent Angotti's 2019 pay jumps 22% to $2.1M
April 24, 2020
AcelRx Pharmaceuticals CEO Vincent Angotti's 2018 pay falls 26% to $1.7M
May 14, 2019